<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37415045</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>12</Day></DateCompleted><DateRevised><Year>2023</Year><Month>10</Month><Day>14</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2576</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Inflammation</Title><ISOAbbreviation>Inflammation</ISOAbbreviation></Journal><ArticleTitle>Coordinated Priming of NKG2D Pathway by IL-15 Enhanced Functional Properties of Cytotoxic CD4<sup>+</sup>CD28<sup>-</sup>&#x2009;T Cells Expanded in Systemic Lupus Erythematosus.</ArticleTitle><Pagination><StartPage>1587</StartPage><EndPage>1601</EndPage><MedlinePgn>1587-1601</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10753-023-01860-z</ELocationID><Abstract><AbstractText>Systemic lupus erythematosus (SLE) is a systemic autoimmune disorder, and numerous aberrations of T cell responses have been reported and were implicated in its pathophysiology. Recently, CD4-positive T cells with cytotoxic potential were shown to be involved in autoimmune disease progression and tissue damage. However, the effector functions of this cell type and their potential molecular mechanisms in SLE patients remain to be elucidated. In this study, we find that cytotoxic CD4<sup>+</sup>CD28<sup>-</sup> T cells are expanded in SLE patients with flow cytometry analysis, and the percentage of CD4<sup>+</sup>CD28<sup>-</sup> T cells positively correlates with the Systemic Lupus International Collaborating Clinics/ACR Damage Index (SDI). Furthermore, our study suggests that interleukin-15 (IL-15) promotes the expansion, proliferation, and cytotoxic function of CD4<sup>+</sup>CD28<sup>-</sup> T cells in SLE patients through activation of the Janus kinase3-STAT5 pathway. Further study indicates that IL-15 not only mediates the upregulation of NKG2D, but also cooperates with the NKG2D pathway to regulate the activation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) pathway. Together, our study demonstrated that proinflammatory and cytolytic CD4<sup>+</sup>CD28<sup>-</sup> T cells expand in SLE patients. The pathogenic potential of these CD4<sup>+</sup>CD28<sup>-</sup> T cells is driven by the coupling of the IL-15/IL-15R signaling pathway and the NKG2D/DAP10 signaling pathway, which may open new avenues for therapeutic intervention to prevent SLE progression.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Tingting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wei</LastName><ForeName>Laiyou</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen People's Hospital, The Frist Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Shuhui</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Wencong</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yulan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Heng</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Qianqian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Integrated Chinese and Western Medicine Postdoctoral Research Station, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Zhenyou</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Microbiology and Immunology, College of Basic Medicine and Public Hygiene, Jinan University, Guangzhou, 510632, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dongzhou</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen People's Hospital, The Frist Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ren</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. hong_xiaoping@hotmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Xiaoping</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Rheumatology and Immunology, The Second Clinical Medical College, Jinan University (Shenzhen People's Hospital), Shenzhen, 518020, China. renh@sustech.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Southern University of Science and Technology, Shenzhen, 518055, China. renh@sustech.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Shenzhen People's Hospital, The Frist Affiliated Hospital of Southern University of Science and Technology, Shenzhen, 518020, China. renh@sustech.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>82201996</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>81971464</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>2021A1515111072</GrantID><Agency>Guangdong Basic and Applied Basic Research Fund</Agency><Country/></Grant><Grant><GrantID>JCYJ20220530151811025</GrantID><Agency>Science and innovation commission of shenzhen municipality</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>07</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Inflammation</MedlineTA><NlmUniqueID>7600105</NlmUniqueID><ISSNLinking>0360-3997</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018106">CD28 Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019409">Interleukin-15</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055655">NK Cell Lectin-Like Receptor Subfamily K</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.1.-</RegistryNumber><NameOfSubstance UI="D019869">Phosphatidylinositol 3-Kinases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000970">Antineoplastic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018106" MajorTopicYN="N">CD28 Antigens</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019409" MajorTopicYN="N">Interleukin-15</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055655" MajorTopicYN="N">NK Cell Lectin-Like Receptor Subfamily K</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019869" MajorTopicYN="N">Phosphatidylinositol 3-Kinases</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000970" MajorTopicYN="Y">Antineoplastic Agents</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cytolytic function</Keyword><Keyword MajorTopicYN="N">cytotoxic CD4+CD28&#x2212; T cells</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">interleukin-15-NKG2D</Keyword><Keyword MajorTopicYN="N">tissue damage</Keyword></KeywordList><CoiStatement>The authors declared no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>5</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>7</Month><Day>7</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>7</Month><Day>6</Day><Hour>23</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37415045</ArticleId><ArticleId IdType="pmc">PMC10567942</ArticleId><ArticleId IdType="doi">10.1007/s10753-023-01860-z</ArticleId><ArticleId IdType="pii">10.1007/s10753-023-01860-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ohl K, Tenbrock K. Inflammatory cytokines in systemic lupus erythematosus. Journal of Biomedicine &amp; Biotechnology. 2011;2011:432595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196871</ArticleId><ArticleId IdType="pubmed">22028588</ArticleId></ArticleIdList></Reference><Reference><Citation>Dema, B., and N. Charles. 2016. Autoantibodies in SLE: specificities, isotypes and receptors. Antibodies (Basel) 5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6698872</ArticleId><ArticleId IdType="pubmed">31557984</ArticleId></ArticleIdList></Reference><Reference><Citation>Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: Recent advances. Trends in Molecular Medicine. 2010;16:47&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2823952</ArticleId><ArticleId IdType="pubmed">20138006</ArticleId></ArticleIdList></Reference><Reference><Citation>Almaani S, Meara A, Rovin BH. Update on lupus nephritis. Clinical Journal of the American Society of Nephrology. 2017;12:825&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5477208</ArticleId><ArticleId IdType="pubmed">27821390</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsky PE. Systemic lupus erythematosus: An autoimmune disease of B cell hyperactivity. Nature Immunology. 2001;2:764&#x2013;766.</Citation><ArticleIdList><ArticleId IdType="pubmed">11526379</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton VR, Tsokos GC. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis Research &amp; Therapy. 2011;13:207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3132009</ArticleId><ArticleId IdType="pubmed">21457530</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton VR, Tsokos GC. T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. The Journal of Clinical Investigation. 2015;125:2220&#x2013;2227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4497749</ArticleId><ArticleId IdType="pubmed">25961450</ArticleId></ArticleIdList></Reference><Reference><Citation>Rother N, van der Vlag J. Disturbed T cell signaling and altered Th17 and regulatory T cell subsets in the pathogenesis of systemic lupus erythematosus. Frontiers in Immunology. 2015;6:610.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4663269</ArticleId><ArticleId IdType="pubmed">26648939</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton VR, Suarez-Fueyo A, Meidan E, Li H, Mizui M, Tsokos GC. Pathogenesis of human systemic lupus erythematosus: A cellular perspective. Trends in Molecular Medicine. 2017;23:615&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5650102</ArticleId><ArticleId IdType="pubmed">28623084</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsuyama T, Tsokos GC, Moulton VR. Aberrant T cell signaling and subsets in systemic lupus erythematosus. Frontiers in Immunology. 2018;9:1088.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5967272</ArticleId><ArticleId IdType="pubmed">29868033</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilstra JS, Avery L, Menk AV, Gordon RA, Smita S, Kane LP, et al. Kidney-infiltrating T cells in murine lupus nephritis are metabolically and functionally exhausted. The Journal of Clinical Investigation. 2018;128:4884&#x2013;4897.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6205402</ArticleId><ArticleId IdType="pubmed">30130253</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Z, Wang Y, Li R, Huang H, Wang R. Use of laser microdissection in the analysis of renal-infiltrating T cells in murine lupus. Cent Eur J Immunol. 2014;39:285&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439994</ArticleId><ArticleId IdType="pubmed">26155137</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake K, Akahoshi M, Nakashima H. Th subset balance in lupus nephritis. Journal of Biomedicine &amp; Biotechnology. 2011;2011:980286.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3163408</ArticleId><ArticleId IdType="pubmed">21904445</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwata Y, Furuichi K, Kaneko S, Wada T. The role of cytokine in the lupus nephritis. Journal of Biomedicine &amp; Biotechnology. 2011;2011:594809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3199078</ArticleId><ArticleId IdType="pubmed">22028590</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W, Zhu P, Wang Y, Wang Z. Follicular helper T cells in systemic lupus erythematosus: A potential therapeutic target. Autoimmunity Reviews. 2011;10:299&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">21111068</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatadri R, Sabapathy V, Dogan M, Sharma R. Targeting regulatory T cells for therapy of lupus nephritis. Frontiers in Pharmacology. 2021;12:806612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8775001</ArticleId><ArticleId IdType="pubmed">35069220</ArticleId></ArticleIdList></Reference><Reference><Citation>Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine. 2015;72:146&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">25647269</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawlik A, Ostanek L, Brzosko I, Brzosko M, Masiuk M, Machalinski B, et al. The expansion of CD4+CD28&#x2212; T cells in patients with rheumatoid arthritis. Arthritis Research &amp; Therapy. 2003;5:R210&#x2013;R213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC165060</ArticleId><ArticleId IdType="pubmed">12823856</ArticleId></ArticleIdList></Reference><Reference><Citation>Broadley I, Pera A, Morrow G, Davies KA, Kern F. Expansions of cytotoxic CD4(+)CD28(-) T cells drive excess cardiovascular mortality in rheumatoid arthritis and other chronic inflammatory conditions and are triggered by CMV infection. Frontiers in Immunology. 2017;8:195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5332470</ArticleId><ArticleId IdType="pubmed">28303136</ArticleId></ArticleIdList></Reference><Reference><Citation>Broux B, Pannemans K, Zhang X, Markovic-Plese S, Broekmans T, Eijnde BO, et al. CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. Journal of Autoimmunity. 2012;38:10&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">22123179</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun W, Zheng L, Huang L. Role of unusual CD4+ CD28&#x2212; T cells in acute coronary syndrome. Molecular Biology Reports. 2012;39:3337&#x2013;3342.</Citation><ArticleIdList><ArticleId IdType="pubmed">21695428</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumitriu IE, Baruah P, Finlayson CJ, Loftus IM, Antunes RF, Lim P, et al. High levels of costimulatory receptors OX40 and 4&#x2013;1BB characterize CD4+CD28null T cells in patients with acute coronary syndrome. Circulation Research. 2012;110:857&#x2013;869.</Citation><ArticleIdList><ArticleId IdType="pubmed">22282196</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattoo H, Mahajan VS, Maehara T, Deshpande V, Della-Torre E, Wallace ZS, et al. Clonal expansion of CD4(+) cytotoxic T lymphocytes in patients with IgG4-related disease. The Journal of Allergy and Clinical Immunology. 2016;138:825&#x2013;838.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014627</ArticleId><ArticleId IdType="pubmed">26971690</ArticleId></ArticleIdList></Reference><Reference><Citation>Maehara T, Mattoo H, Ohta M, Mahajan VS, Moriyama M, Yamauchi M, et al. Lesional CD4+ IFN-gamma+ cytotoxic T lymphocytes in IgG4-related dacryoadenitis and sialoadenitis. Annals of the Rheumatic Diseases. 2017;76:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435236</ArticleId><ArticleId IdType="pubmed">27358392</ArticleId></ArticleIdList></Reference><Reference><Citation>Maly K, Schirmer M. The story of CD4+ CD28&#x2212; T cells revisited: Solved or still ongoing? Journal of Immunology Research. 2015;2015:348746.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4365319</ArticleId><ArticleId IdType="pubmed">25834833</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GH, Lee WW. Unusual CD4(+)CD28(-) T cells and their pathogenic role in chronic inflammatory disorders. Immune Netw. 2016;16:322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5195841</ArticleId><ArticleId IdType="pubmed">28035207</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeuchi A, Saito T. CD4 CTL, a cytotoxic subset of CD4(+) T cells, their differentiation and function. Frontiers in Immunology. 2017;8:194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5321676</ArticleId><ArticleId IdType="pubmed">28280496</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenerenti M, Saillard M, Romero P, Jandus C. The era of cytotoxic CD4 T cells. Frontiers in Immunology. 2022;13:867189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9094409</ArticleId><ArticleId IdType="pubmed">35572552</ArticleId></ArticleIdList></Reference><Reference><Citation>Allez M, Tieng V, Nakazawa A, Treton X, Pacault V, Dulphy N, et al. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions. Gastroenterology. 2007;132:2346&#x2013;2358.</Citation><ArticleIdList><ArticleId IdType="pubmed">17570210</ArticleId></ArticleIdList></Reference><Reference><Citation>Saez-Borderias A, Guma M, Angulo A, Bellosillo B, Pende D, Lopez-Botet M. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus. European Journal of Immunology. 2006;36:3198&#x2013;3206.</Citation><ArticleIdList><ArticleId IdType="pubmed">17109473</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Torre E, Bozzalla-Cassione E, Sciorati C, Ruggiero E, Lanzillotta M, Bonfiglio S, et al. A CD8alpha- subset of CD4+SLAMF7+ cytotoxic T cells is expanded in patients with IgG4-related disease and decreases following glucocorticoid treatment. Arthritis &amp; Rhematology. 2018;70:1133&#x2013;1143.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6019645</ArticleId><ArticleId IdType="pubmed">29499100</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosmaczewska A, Ciszak L, Stosio M, Szteblich A, Madej M, Frydecka I, et al. CD4(+)CD28(null) T cells are expanded in moderately active systemic lupus erythematosus and secrete pro-inflammatory interferon gamma, depending on the Disease Activity Index. Lupus. 2020;29:705&#x2013;714.</Citation><ArticleIdList><ArticleId IdType="pubmed">32279585</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Sanchez-Zuniga C, Gamboa-Cardenas RV, Aliaga-Zamudio M, Zevallos F, Tineo-Pozo G, et al. Circulating CD4+CD28null and extra-thymic CD4+CD8+ double positive T cells are independently associated with disease damage in systemic lupus erythematosus patients. Lupus. 2016;25:233&#x2013;240.</Citation><ArticleIdList><ArticleId IdType="pubmed">26385221</ArticleId></ArticleIdList></Reference><Reference><Citation>Ugarte-Gil MF, Sanchez-Zuniga C, Gamboa-Cardenas RV, Aliaga-Zamudio M, Zevallos F, Mosqueira-Riveros A, et al. Peripheral CD4+CD28null T-cells as predictors of damage in systemic lupus erythematosus patients. Clinical and Experimental Rheumatology. 2018;36:1008&#x2013;1013.</Citation><ArticleIdList><ArticleId IdType="pubmed">29745892</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism. 2012;64:2677&#x2013;2686.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman DD, Ibanez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. Journal of Rheumatology. 2002;29:288&#x2013;291.</Citation><ArticleIdList><ArticleId IdType="pubmed">11838846</ArticleId></ArticleIdList></Reference><Reference><Citation>Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis and Rheumatism. 1996;39:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">8607884</ArticleId></ArticleIdList></Reference><Reference><Citation>Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Journal of the American Society of Nephrology. 2004;15:241&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">14747370</ArticleId></ArticleIdList></Reference><Reference><Citation>Serroukh, Y., C. Gu-Trantien, B. Hooshiar Kashani, M. Defrance, T.P. Vu Manh, A. Azouz, et al. 2018. The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes. Elife 7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5844691</ArticleId><ArticleId IdType="pubmed">29488879</ArticleId></ArticleIdList></Reference><Reference><Citation>Allard-Chamard H, Mishra HK, Nandi M, Mayhue M, Menendez A, Ilangumaran S, et al. Interleukin-15 in autoimmunity. Cytokine. 2020;136:155258.</Citation><ArticleIdList><ArticleId IdType="pubmed">32919253</ArticleId></ArticleIdList></Reference><Reference><Citation>Broux B, Mizee MR, Vanheusden M, van der Pol S, van Horssen J, Van Wijmeersch B, et al. IL-15 amplifies the pathogenic properties of CD4+CD28&#x2212; T cells in multiple sclerosis. The Journal of Immunology. 2015;194:2099&#x2013;2109.</Citation><ArticleIdList><ArticleId IdType="pubmed">25617471</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullenkamp J, Mengoni V, Kaur S, Chhetri I, Dimou P, Astroulakis ZMJ, et al. Interleukin-7 and interleukin-15 drive CD4+CD28null T lymphocyte expansion and function in patients with acute coronary syndrome. Cardiovascular Research. 2021;117:1935&#x2013;1948.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8262639</ArticleId><ArticleId IdType="pubmed">32647892</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JX, Du N, Li P, Kazemian M, Gebregiorgis T, Spolski R, et al. Critical functions for STAT5 tetramers in the maturation and survival of natural killer cells. Nature Communications. 2017;8:1320.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5673064</ArticleId><ArticleId IdType="pubmed">29105654</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington ND, Puthalakath H, Gunn P, Naik E, Michalak EM, Smyth MJ, et al. Interleukin 15-mediated survival of natural killer cells is determined by interactions among Bim, Noxa and Mcl-1. Nature Immunology. 2007;8:856&#x2013;863.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951739</ArticleId><ArticleId IdType="pubmed">17618288</ArticleId></ArticleIdList></Reference><Reference><Citation>Mishra A, Sullivan L, Caligiuri MA. Molecular pathways: Interleukin-15 signaling in health and in cancer. Clinical Cancer Research. 2014;20:2044&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3989546</ArticleId><ArticleId IdType="pubmed">24737791</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts AI, Lee L, Schwarz E, Groh V, Spies T, Ebert EC, et al. NKG2D receptors induced by IL-15 costimulate CD28&#x2212;negative effector CTL in the tissue microenvironment. The Journal of Immunology. 2001;167:5527&#x2013;5530.</Citation><ArticleIdList><ArticleId IdType="pubmed">11698420</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutherland CL, Chalupny NJ, Schooley K, VandenBos T, Kubin M, Cosman D. UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells. The Journal of Immunology. 2002;168:671&#x2013;679.</Citation><ArticleIdList><ArticleId IdType="pubmed">11777960</ArticleId></ArticleIdList></Reference><Reference><Citation>Park YP, Choi SC, Kiesler P, Gil-Krzewska A, Borrego F, Weck J, et al. Complex regulation of human NKG2D-DAP10 cell surface expression: Opposing roles of the gammac cytokines and TGF-beta1. Blood. 2011;118:3019&#x2013;3027.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3291493</ArticleId><ArticleId IdType="pubmed">21816829</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang D, Tian Z, Zhang M, Yang W, Tang J, Wu Y, et al. NKG2D(+)CD4(+) T cells kill regulatory T cells in a NKG2D-NKG2D ligand- dependent manner in systemic lupus erythematosus. Science and Reports. 2017;7:1288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5430709</ArticleId><ArticleId IdType="pubmed">28455530</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Liu X, Zhao Y, Xu X, Liu Y, Wu X. Excessive IL-15 promotes cytotoxic CD4 + CD28&#x2212; T cell-mediated renal injury in lupus nephritis. Immun Ageing. 2022;19:50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9624042</ArticleId><ArticleId IdType="pubmed">36320075</ArticleId></ArticleIdList></Reference><Reference><Citation>Pacheco-Lugo L, Saenz-Garcia J, Navarro Quiroz E, Gonzalez Torres H, Fang L, Diaz-Olmos Y, et al. Plasma cytokines as potential biomarkers of kidney damage in patients with systemic lupus erythematosus. Lupus. 2019;28:34&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">30453818</ArticleId></ArticleIdList></Reference><Reference><Citation>Baranda L, de la Fuente H, Layseca-Espinosa E, Portales-Perez D, Nino-Moreno P, Valencia-Pacheco G, et al. IL-15 and IL-15R in leucocytes from patients with systemic lupus erythematosus. Rheumatology (Oxford) 2005;44:1507&#x2013;1513.</Citation><ArticleIdList><ArticleId IdType="pubmed">16251219</ArticleId></ArticleIdList></Reference><Reference><Citation>Horng T, Bezbradica JS, Medzhitov R. NKG2D signaling is coupled to the interleukin 15 receptor signaling pathway. Nature Immunology. 2007;8:1345&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pubmed">17952078</ArticleId></ArticleIdList></Reference><Reference><Citation>Billadeau DD, Upshaw JL, Schoon RA, Dick CJ, Leibson PJ. NKG2D-DAP10 triggers human NK cell-mediated killing via a Syk-independent regulatory pathway. Nature Immunology. 2003;4:557&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pubmed">12740575</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali AK, Nandagopal N, Lee SH. IL-15-PI3K-AKT-mTOR: A critical pathway in the life journey of natural killer cells. Frontiers in Immunology. 2015;6:355.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4507451</ArticleId><ArticleId IdType="pubmed">26257729</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X, Zhao XY. Transcription factors associated with IL-15 cytokine signaling during NK cell development. Frontiers in Immunology. 2021;12:610789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013977</ArticleId><ArticleId IdType="pubmed">33815365</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>